App-Quantinova.ai

Proton radiotherapy for incurable recurrent or metastatic cancers of the head and neck by the RTOG 8502 hypofractionated palliative schedule.

Benjamin H. Lok - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

N/A

Results of long-term follow-up for patients with advanced gastrointestinal stromal tumor underwent palliative surgery after tyrosine kinase inhibitors therapy.

Haibo Qiu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastrointestinal stromal tumor

L-Tyrosine

Conjoined hyperactivation of the RAS and PI3K pathways in advanced GIST.

Bin Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

PDGFRA rearrangement

N/A

Apatinib for patients with advanced sarcoma: Initial clinical experience.

Na Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Soft tissue sarcoma

Apatinib

The role of transforming growth factor-1 signaling pathway during the process of angiogenesis induced by chronic stress in colorectal cancer.

Jie Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Bevacizumab

Bevacizumab effectiveness and tumor vessel subtypes in metastatic colorectal cancer patients.

Wen-zhuo He - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Bevacizumab

Insulin growth factor-2 binding protein 3 (IGF2BP3) to promote lung tumorigenesis viaregulation of p53 stability.

Wei Zhao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Glypican-5 to suppress NSCLC metastasis and EMT process by blocking Wnt/-catenin signaling pathway.

Mantang Qiu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Predicting long-term prognosis using targeted cell free DNA sequencing in resectable pancreatic cancer patients.

Bo Song - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Comparison of plasma ctDNA from the portal and peripheral veins of resectable CRC patients.

Xin-Xing Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Comparative analysis of the representative value of somatic mutation profiles derived from ctDNA and other updated lung tumor biopsy alternative in non-resectable non-small cell lung cancer patients.

Xiaozheng Kang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Association of mutant EGFR concentration in circulating cell-free DNA (cfDNA) by ddPCR with tumor burden and prognosis in NSCLC patients treated with EGFR-TKIs.

Yan-juan Zhu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Identification of APE1 as a chemotherapeutic prognostic marker for non-small cell lung cancer patients.

Mengxia Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Circulating tumor DNA(ctDNA) testing to detect identical gene mutation rates of KRAS, NRAS, PIK3CA and P53 compared to tissue-based testing and reflects treatment efficacy in patients with colorectal cancer.

Yanhong Deng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

The largest sample size (2,200 cases) pooled analysis of LT-PCR achieving quantitative determination of folate receptor-positive CTCs for lung cancer in China.

Caicun Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

An ultra-deep next generation sequencing method for cfDNA detection in NSCLC patients.

Yu Yao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Relationship of RRM1 compared to ERCC1 gene in peripheral blood to the efficacy of the gemictable chemotherapy in advanced non-small cell lung cancer.

Xue-Lin Zou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Gemcitabine

Circulating Let-7 as a prognostic factor and potential agent to detect accelerated reproliferation during radiotherapy in lung cancer.

Xiaolin Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Correlation between PD-L1 expression and pre-existing immune status in IIIA lung adenocarcinoma.

Lequn Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Single cell copy number variation analysis of circulating tumor cells in gastrointestinal cancer patients for study of intra-patient genomic heterogeneity.

Man Chun Leong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Filters

24782 Abstracts